Rethinking screening for breast cancer and prostate cancer.
暂无分享,去创建一个
[1] R. DiPaola,et al. Contemporary risk profile of prostate cancer in the United States. , 2009, Journal of the National Cancer Institute.
[2] B. Fisher,et al. National Surgical Adjuvant Breast and Bowel Project , 2020, Definitions.
[3] David Chia,et al. Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.
[4] Ziding Feng,et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. , 2006, Journal of the National Cancer Institute.
[5] Karla Kerlikowske,et al. Pathologic findings from the Breast Cancer Surveillance Consortium , 2006, Cancer.
[6] I. Thompson,et al. Does the level of prostate cancer risk affect cancer prevention with finasteride? , 2008, Urology.
[7] K. Kerlikowske,et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. , 2002, Journal of the National Cancer Institute.
[8] J. Peto,et al. The cervical cancer epidemic that screening has prevented in the UK , 2004, The Lancet.
[9] S Toikkanen,et al. Cured of breast cancer? , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] E. Greenberg,et al. Changes in prostate cancer incidence and treatment in USA , 1994, The Lancet.
[11] A. Miller. Screening for breast cancer with mammography , 2001, The Lancet.
[12] K. Kerlikowske,et al. Incidence of and treatment for ductal carcinoma in situ of the breast. , 1996, JAMA.
[13] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[14] J. Meuwly,et al. [Active surveillance for early-stage prostate cancer]. , 2009, Revue medicale suisse.
[15] E. Burnside,et al. The impact of alternative practices on the cost and quality of mammographic screening in the United States. , 2001, Clinical breast cancer.
[16] Nancy Breen,et al. Progress in cancer screening practices in the United States , 2003, Cancer.
[17] Michael J Barry,et al. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut , 2002, BMJ : British Medical Journal.
[18] J. Stanford,et al. Screening, Treatment, and Prostate Cancer Mortality in the Seattle Area and Connecticut: Fifteen-year Follow-up , 2008, Journal of General Internal Medicine.
[19] F. Berthold,et al. Children may not benefit from neuroblastoma screening at 1 year of age. Updated results of the population based controlled trial in Germany. , 2003, Cancer letters.
[20] A. Jemal,et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. , 2003, Journal of the National Cancer Institute.
[21] D. Gunnell,et al. Comparison of trends in prostate-cancer mortality in England and Wales and the USA , 2000, The Lancet.
[22] S. Linn,et al. Evaluation of the effect of screening on the detection of good and poor prognosis breast cancers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Leif E. Peterson,et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] E. Metter,et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. , 2007, The Journal of urology.
[25] T. Tammela,et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. , 2009, European urology.
[26] S. Corson. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes , 2006 .
[27] J. Cuzick,et al. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. , 2007, Journal of the National Cancer Institute.
[28] Donald E Bailey,et al. Active surveillance for early‐stage prostate cancer , 2008, Cancer.
[29] T. Wilt,et al. The prostate cancer intervention versus observation trial , 1994 .
[30] Eric J Feuer,et al. The decrease in breast-cancer incidence in 2003 in the United States. , 2007, The New England journal of medicine.
[31] M. Mushinski,et al. Probabilities of eventually developing or dying of cancer—united states, 1985 , 1985, CA: a cancer journal for clinicians.
[32] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[33] Ugo Pastorino,et al. Computed tomography screening and lung cancer outcomes. , 2007, JAMA.
[34] D. Berry,et al. Effect of screening and adjuvant therapy on mortality from breast cancer , 2005 .
[35] P. Schellhammer,et al. High-Grade Prostate Cancer and the Prostate Cancer Prevention Trial , 2008, Cancer Prevention Research.
[36] M. Cooperberg,et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. , 2004, The Journal of urology.
[37] J. Crowley,et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.
[38] S. Woolf,et al. Breast Cancer Screening: A Summary of the Evidence for the U.S. Preventive Services Task Force , 2002, Annals of Internal Medicine.
[39] H. Welch,et al. The natural history of invasive breast cancers detected by screening mammography. , 2008, Archives of internal medicine.
[40] Karen A Gelmon,et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] Michael M Lieber,et al. Journal Review , 2003, International Society of Hair Restoration Surgery.
[42] H. Welch. Overdiagnosis and mammography screening , 2009, BMJ : British Medical Journal.
[43] K. Malone,et al. Age-Specific Incidence Rates of In situ Breast Carcinomas by Histologic Type, 1980 to 2001 , 2005, Cancer Epidemiology Biomarkers & Prevention.
[44] J. Elmore,et al. Ten-year risk of false positive screening mammograms and clinical breast examinations. , 1998, The New England journal of medicine.
[45] Ingvar Andersson,et al. Long-term effects of mammography screening: updated overview of the Swedish randomised trials , 2002, The Lancet.
[46] T. Rebbeck,et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. , 2002, Journal of the National Cancer Institute.
[47] Adam S. Kibel,et al. Screening and Prostate-Cancer Mortality in a Randomized European Study , 2009 .
[48] Jun Luo,et al. Copy Number Analysis Indicates Monoclonal Origin of Lethal Metastatic Prostate Cancer , 2009, Nature Medicine.
[49] A. Jemal,et al. Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.
[50] C. Perou,et al. Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] T. Wilt,et al. The prostate cancer intervention versus observation trial (PIVOT). A randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer , 1995, Oncology.
[52] Shannon K. McDonnell,et al. EFFICACY OF BILATERAL PROPHYLACTIC MASTECTOMY IN WOMEN WITH A FAMILY HISTORY OF BREAST CANCER , 1999 .
[53] L. V. van't Veer,et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. , 2006, Journal of the National Cancer Institute.
[54] I. Thompson,et al. Finasteride Does Not Increase the Risk of High-Grade Prostate Cancer: A Bias-Adjusted Modeling Approach , 2008, Cancer Prevention Research.
[55] C. Begg,et al. Computed Tomography Screening and Lung Cancer Outcomes , 2008 .
[56] Karla Kerlikowske,et al. Comparison of screening mammography in the United States and the United kingdom. , 2003, JAMA.
[57] A. DeMichele,et al. Detection of locally advanced breast cancer in the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657) in the interval between routine screening. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] I. Thompson,et al. Active surveillance for prostate cancer. , 2010, JAMA.
[59] I. Thompson,et al. Pathologic Characteristics of Cancers Detected in the Prostate Cancer Prevention Trial: Implications for Prostate Cancer Detection and Chemoprevention , 2008, Cancer Prevention Research.
[60] A. Grove,et al. Efficiency in the health care industries: a view from the outside. , 2005, JAMA.
[61] Lisa M. Schwartz,et al. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? , 2003, JAMA.
[62] Ruth Etzioni,et al. It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer. , 2008, The Journal of urology.
[63] L. Esserman,et al. Total Skin-Sparing Mastectomy: Complications and Local Recurrence Rates in 2 Cohorts of Patients , 2009, Annals of surgery.
[64] E. Feuer,et al. SEER Cancer Statistics Review, 1975-2003 , 2006 .
[65] L. Esserman,et al. Neoadjuvant hormonal therapy for ductal carcinoma in situ: Trial design and preliminary results , 2006, Annals of Surgical Oncology.
[66] L. Esserman,et al. Evaluation of breast cancer risk assessment techniques: a cost-effectiveness analysis. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[67] Thea D. Tlsty,et al. Benign breast disease and the risk of breast cancer. , 2005 .
[68] L. Ferrucci,et al. Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability. , 2007, Urology.
[69] P. Ravdin,et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] L. Klotz. Active surveillance for prostate cancer: trials and tribulations , 2008, World Journal of Urology.
[71] S. Winawer. Screening for colorectal cancer. , 1977, JAMA.
[72] D. Ikeda,et al. Interval carcinomas in the Malmö Mammographic Screening Trial: radiographic appearance and prognostic considerations. , 1992, AJR. American journal of roentgenology.
[73] M. Tuchman,et al. Screening of infants and mortality due to neuroblastoma. , 2002, The New England journal of medicine.
[74] Joan Austoker,et al. Breast Cancer Screening , 1988 .
[75] Norman Wolmark,et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.
[76] Peter C Gøtzsche,et al. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends , 2009, BMJ : British Medical Journal.
[77] J. Garber,et al. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. , 2000, JAMA.
[78] S. Linn,et al. Evaluation of the effect of screening on the detection of good and poor prognosis breast cancers , 2009 .
[79] C. Laronga,et al. Total Skin-Sparing Mastectomy: Complications and Local Recurrence Rates in 2 Cohorts of Patients , 2009 .